| Business Summary | | Palatin
Technologies
Inc.
is
in
the
early
stages
of
developing
pharmaceutical
products
and
technologies.
The
Company
is
concentrating
its
efforts
on
the
following:
MIDAS,
a
peptide
technology
which
may
be
useful
to
develop
drugs
to
treat
diseases
or
for
diagnostic
imaging;
PT-141,
a
drug
to
treat
sexual
dysfunction,
initially
male
erectile
dysfunction;
and
LeuTech,
a
diagnostic
imaging
product
used
to
image
and
locate
the
site
of
infection
or
inflammation
within
the
body. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | PTN
a
development
stage
biopharmaceutical
co.,
is
engaged
in
the
development
of
products
and
technologies
for
diagnostic
imaging
and
ethical
drug
development
utilizing
peptide.
The
three
main
products
are
MIDAS,
PT-141
and
LeuTech.
For
the
nine
months
ended
3/31/01,
revenues
fell
61%
to
$1.6
million.
Net
loss
rose
11%
to
$6.7
million.
Revenues
reflect
decreased
shared
development
costs
with
LeuTech.
Higher
loss
was
partially
offset
by
decreased
administrative
salaries. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Prendergast, Ph.D., 46 Interim
Chairman | -- | Carl Spana, Ph.D., 38 Pres,
CEO, Director | $247K | Stephen Wills, 43 CFO,
Exec. VP, Sec., Treasurer | 207K | Charles Putnam, 47 Exec.
VP, Director | 295K | Perry Molinoff, M.D., 61 Exec.
VP, R&D | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|